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Abstract
Fenofibrate (FF) lowers plasma triglycerides via PPARa activation. Here, we analyzed lipidomic changes upon FF treatment
of fructose fed rats. Three groups with 6 animals each were defined as control, fructose-fed and fructose-fed/FF treated.
Male Wistar Unilever Rats were subjected to 10% fructose-feeding for 20 days. On day 14, fenofibrate treatment (100 mg/kg
p.o.) was initiated and maintained for 7 days. Lipid species in serum were analyzed using mass spectrometry (ESI-MS/MS; LC-
FT-MS, GC-MS) on days 0, 14 and 20 in all three groups. In addition, lipid levels in liver and intestine were determined. Short-
chain TAGs increased in serum and liver upon fructose-feeding, while almost all TAG-species decreased under FF treatment.
Long-chain unsaturated DAG-levels (36:1, 36:2, 36:4, 38:3, 38:4, 38:5) increased upon FF treatment in rat liver and decreased
in rat serum. FAs, especially short-chain FAs (12:0, 14:0, 16:0) increased during fructose-challenge. VLDL secretion increased
upon fructose-feeding and together with FA-levels decreased to control levels during FF treatment. Fructose challenge of
de novo fatty acid synthesis through fatty acid synthase (FAS) may enhance the release of FAs#16:0 chain length, a process
reversed by FF-mediated PPARa-activation.
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Introduction
Fibrates such as fenofibrate (FF) are widely used in human
medicine for their hypolipidemic effects [1,2]. They belong to a
larger group of molecules called peroxisomal proliferators (PPs)
[3]. PPs activate the peroxisome proliferator activated receptor a
(PPARa) and modulate genes involved in lipid metabolism [4–7].
PPARa activation decreases several mediators of vascular damage
such as lipotoxicity, inflammation, ROS, endothelial dysfunction,
angiogenesis and thrombosis through modulation of cell signaling
related to microvascular dysfunction [2]. PPARa modulators are
linked to species-specific regulation of genes important in cell
growth and differentiation [8]. In rodents, PPARa activation is
associated with peroxisome proliferation and hepatocellular
carcinoma [9]. However, due to species differences at the
molecular level of PPARa regulation, humans might be resistant
to liver cancer induced by PPARa agonists [9–11]. Oxidative
stress due to excessive H2O2-generation upon FF treatment leads
to lipid peroxidation and oxidative DNA damage and hepato-
carcinogenesis in rodents [12–15]. PPARa function is coupled to
several co-activators that interfere with NFkB signaling pathways
linked to carcinogenesis [16]. FF is found enriched in organs of
absorption and elimination, the gut, liver and kidney [17]. The
FIELD-Study (FF Intervention and Event Lowering in Diabetes)
reported a robust and sustained decrease in plasma triglyceride-
levels upon FF treatment [11]. In contrast, elevation of HDL-
cholesterol and Apo A1 levels were less than expected and
decreased progressively over the duration of the study[2]. A recent
study suggests the possible application of HDL molecular
composition for the stratification of patients that could potentially
profit from FF treatment [18]. Recently it was shown that fish oil
and FF treatment showed significant overlap in gene regulation,
with fish oil down-regulating genes in cholesterol and fatty acid
biosynthesis and FF down-regulating genes related to inflamma-
tion [19].
At the molecular level, PPARa forms a heterodimer with
retinoid X receptor (RXR) upon agonist binding and stimulates
the expression of various genes involved in FA b-oxidation and
v-oxidation, intracellular FA-transport and HDL-cholesterol
metabolism [1,20,21]. Unsaturated FAs activate PPARa [22],
and PPARa agonists inhibit the production of prostaglandin E2
(PGE2) in vitro [23]. Through FF activation PPARa decreases
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triglyceride (TAG) and hepatic VLDL-production by enhancing
FA-oxidation in the liver. In addition, it facilitates TAG-removal
by stimulating LPL-production and enhances hepatic lipoprotein
uptake due to the suppression of apo-C-III production [1]. FF also
increases LDL particle size and reduces the prevalence of small
dense LDL (sd LDL) and non-HDL-cholesterol containing
lipoproteins related to apoB. PPARa activation increases HDL-
C by stimulating the production of apo A-I and apo A-II [24,25].
Feeding previously fasted animals a low-fat/high-carbohydrate
diet caused a marked induction of enzymes involved in catalyzing
fatty acid desaturation [26], including ATP citrate lyase [27], FAS
for lipogenesis [28], and SCD-1, which introduces a double bond
in sn-9 position of a variety of fatty acyl CoA precursors [29].
SCD-1 is also a major player regulating the fatty acid composition
of tissues [30], and SCD -/- mice are resistant to diet induced
obesity [31]. Expression of SCD-1 in the liver of diabetic rats was
found to be up-regulated, while D5-desaturase (FADS1) was not
altered [32]. SCD-1 is regarded as a target for reversal of hepatic
steatosis and insulin resistance [28]. FAS is a key enzyme of de
novo lipogenesis, which catalyzes the terminal steps of FA-
synthesis in the liver [28].
In rats, FF also induces carnitine-acetyltransferase (CAT),
carnitine-palmitoyltransferase (CPT), fatty acyl oxidizing system
(FAOS) and acetyl CoA oxidase 1 (Aco1) [12]. FF treatment of
metabolic syndrome patients reduced plasma TAG-levels (30%)
and also cholesterol (30%) in TAG-rich lipoproteins, together with
a reduction of apo CIII and sdLDL and an increase in large LDL,
but did not lower concentrations or turnover rates of NEFAs, nor
did it change glucose or insulin responses to oral glucose challenge
[33]. FF in this study modified FA-metabolism either in the liver or
in TAG-rich lipoproteins but not in adipose tissue due to PPARa
activation.
Dietary exposure to fructose may specifically provide lipid
deposition in visceral adipose tissue, particularly in males, whereas
glucose consumption appears to favor lipid deposition in
subcutaneous adipose tissue [34]. Coingestion of fructose may
elicit an unfavorable TAG-profile similar to fructose alone.
Fructose feeding also induces ChREBP and increases the
expression of lipogenic genes (FAS, ACC, SCD1).
The objective of this study was to investigate the effect of FF
treatment on rats under metabolic overload conditions at the level
of lipid species to get a more detailed insight into lipid metabolism
than with the total level of lipid classes (like total TAG). Metabolic
overload was induced in a rat model by fructose feeding, and
serum, liver and jejunum samples of FF-treated animals and
control groups were analyzed using ESI-MS/MS, ion trap LC-FT-
MS and GC-MS techniques.
Materials and Methods
Study design
The animal studies were performed at Sanofi in Frankfurt-
Ho¨chst. The tissue and serum samples were taken from two
different animal studies with the same basic design. The VLDL-
data was derived from a third study. All experimental procedures
were conducted according to the German Animal Protection Law.
The animal studies were approved by the Sanofi-Aventis Deutsch-
land GmbH institutional animal care and use committee and
notified to the relevant authority. The institution is AAALAC
accredited (AAALAC, 2012). Blood was drawn from the retro-
orbital vein plexus under Isofluran CP (CP Pharma, Burgdorf,
Germany) oxygen/nitric oxide anesthesia (3.5%, 2:1) Animals
were anesthetized in a gas box. The animals were sacrificed by
bleeding from the abdominal aorta under deep Isofluran CP (CP
Pharma, Burgdorf, Germany) oxygen/nitric oxide anesthesia
(3.5%, 2:1). The anesthesia was initiated in gas box and sustained
with mask. In all cases treatment was applied between 7:30 and
8:30 a. m. and blood samples were drawn 1 hour after treatment.
Tissue samples (study 1). Male Wistar rats (HsdCpb: WU)
were obtained from Harlan Laboratories, NL and were used at the
age of 10 weeks for the study. Animals were housed under
controlled temperature (21–23uC), humidity (55%) in Macrolon
type 4 cages (3 animals per cage) with a 12 h light-dark-circle with
ad libitum access to drinking water. Animals were divided into 3
groups with group 1 receiving a standard diet (Ssniff), group 2
receiving a 10% fructose-challenge through drinking-water and
group 3 receiving FF treatment through oral application and a
10%-fructose-challenge through drinking water. The study proto-
col ran for 14 days. In the FF treatment group, drug application
(100 mg/kg p.o.) started at day 7 and lasted for 7 days. After the
treatment period, the heart, the liver and the jejunum were
extracted and stored at 220uC for lipid analysis.
Serum samples (study 2). Male SPRD rats were obtained
from Charles River Laboratories (Wilmington MA) and were used
at the age of 10 weeks for the study. Animals were housed under
controlled temperature (21–23uC), humidity (55%) in Macrolon
type 4 cages (3 animals per cage) with a 12 h light-dark-circle with
ad libitum access to drinking water. Animals were divided into 3
groups with group 1 receiving a standard diet, group 2 receiving a
10% fructose-challenge through drinking-water and group 3
receiving FF treatment through oral application and a 10%-
fructose-challenge through drinking water. The study protocol ran
for 20 days. In the FF treatment group, drug application (100 mg/
kg p.o.) started at day 14 and lasted for 7 days. Serum samples
were taken before start of the fructose treatment (day 0), after 14
days of fructose treatment but before FF treatment (day 14) and at
the end of the FF treatment (day 20). Samples were stored at
280uC until lipid analysis.
VLDL-secretion (study 3). Male Wistar rats (HsdCpb: WU)
were obtained from Harlan Laboratories, NL and were used at the
age of 10 weeks for the study. Animals were housed under
controlled temperature (21–23uC), humidity (55%) in Macrolon
type 4 cages (3 animals per cage) with a 12 h light-dark-circle with
ad libitum access to drinking water. Animals were divided into 3
groups with group 1 receiving a standard diet, group 2 receiving a
10% fructose-challenge through drinking-water and group 3
receiving FF treatment through oral application and a 10%-
fructose-challenge through drinking water. The study protocol ran
for 14 days. In the FF treatment group, drug application (100 mg/
kg p.o.) started at day 7 and lasted for 7 days. After 6 days the
animals were fasted for approx. 23 h; then, Tyloxapol reagent
(Sigma, 1:10 diluted with NaCl 0.9%) was applied and samples
were taken after 1, 2, 4 and 6 hours.
Clinical chemistry
Serum levels of cholesterol, triglycerides, and phospholipids, as
well as the safety variables: aspartate transaminase (ASAT),
alanine transaminase (ALAT), alkaline phosphatase (AP) were
determined on a Roche Cobas 6000 at Sanofi in Frankfurt Ho¨chst
using the respective Roche clinical chemistry kits for human
diagnostics. Assays were performed according to the instructions
from the suppliers.
Statistical analysis
Data are presented as mean6s.d.. Significant differences were
calculated by an unpaired Mann-Whitney-U test. Two-point
comparisons were performed. The two groups consisted of
the fructose-free control group which was compared to the
Fenofibrate Treatment of Fructose-Fed Rats - Neutral Lipids
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fructose-fed-group to establish the influence of the feeding itself.
The second significance was determined between the fructose-fed-
group and the Fenofibrate-treatment-group. For all statistical
calculations, SPSS Statistics 19 software (IBM) was used. A P,
0.05 was considered to be statistically significant (P,0.05 is
denoted by *; P,0.01 is denoted by **).
Lipid measurements
Analysis of TAG/DAG-species was performed according to
published methods [35]. In brief, 30 ml serum were extracted with
a mixture of methyl tert-butyl ether, methanol and water (MTBE/
MeOH/H2O; 10:3:2.5, v/v/v; 9.77 ml total volume) according to
Matyash et al. [36]. Lipid extracts were spiked with a 1 mMmix of
18 LIPID MAPS internal standards (LM 6000, LM 6001) and 5 ml
of spiked samples were injected onto a Thermo 1.9 mm Hypersil
GOLD C18, 10061 mm HPLC column mounted in an Accela
HPLC instrument (Thermo Scientific). The final concentrations of
internal TAG- and DAG-standard were 1 and 3 mM respectively.
Solvent A was water with 1% ammonium acetate and 0.1% formic
acid, solvent B was acetonitrile/2-propanol 5:2 (v/v) with 1%
ammonia acetate and 0.1% formic acid. The gradient ran from 35
to 70% B in 4 min, then to 100% B in another 16 min and held
there for further 10 min. The flow rate was 250 ml/min. Data
acquisition was performed by FT-ICR-MS (LTQ-FT, Thermo
Scientific) full scans at a resolution of 200k and ,2 ppm mass
accuracy with external calibration. From the FT-ICR-MS preview
scan, the four most abundant m/z values were picked in data
dependent acquisition (DDA) mode, fragmented in the linear ion
trap and ejected at nominal mass resolution. Normalized collision
energy was set to 35%, repeat count was two and exclusion
duration was 60 s. Quantitative analysis of data acquired by the
platform described above was carried out by Lipid Data Analyzer
[37].
Total hydrolysate FAs were analyzed as FAMEs by GC/MS
according to a recently published method [38]. Briefly, lipids were
extracted with chloroform/methanol according to Bligh and Dyer
[39]. Derivatization was performed as follows. 10 ml serum or cell
homogenate corresponding to 50 mg protein were methylated in
PTFE screw capped Pyrex tubes. 1 mg each of C13:0 and C21:0
iso were added as internal standards in 50 ml methanol. 200 ml of
acetyl-chloride were added and the sample was shaken vigorously
at 20uC for 14 h. Afterwards 5 ml 6% potassium carbonate
solution was added. FAMEs were extracted with 500 ml n-hexane.
100 ml of the n-hexane top layer was transferred into a 500 ml
auto-sampler vial and crimped. Analysis of the NEFA fraction was
performed after Dole-extraction [40]. The NEFA-fraction was
separated by SPE-fractionation by a newly developed method
[41]. Derivatization and GC/MS-analysis of this fraction was
performed with the method described above.
Results
Male Wistar rats were subjected to fructose feeding and
subsequent treatment with fenofibrate (FF). Lipidomic analysis
was performed using MS-techniques (for details see materials and
methods).
General values
The clinical chemistry values for total triglycerides, total
cholesterol, total phospholipids and body/liver weight as well as
food/water consumption are shown in table 1. Also added are the
values for the study safety parameters aspartate aminotransferase
(ASAT), alanine aminotransferase (ALAT) and alkaline phospha-
tase (AP). Values are given as means with s.d. where appropriate.
The initial point of time was taken before the start of treatment,
meaning the fructose-fed and the FF groups were on a fructose diet
for one week at that time. These values were determined in the
first rat study, in which the liver and jejunum lipid levels were
measured. The final point of time was after one week of treatment
with FF. Cholesterol, triglycerides and phospholipids were
increased by fructose-feeding, while FF treatment reduced these
levels below control levels. Body weight of the animals was
approximately equal for the three groups at both times, while liver
weight was slightly increased through fructose-feeding and highly
increased after FF treatment. Water consumption was lower for
the fructose-fed animals, while food consumption was almost
doubled upon fructose-feeding and nearly back to control level
upon FF treatment.
Triacylglycerols and diacylglycerols
The weight of liver and heart of the three groups are shown in
Fig 1A. The weight of the heart did not change upon fructose
feeding or FF treatment, while the weight of the liver increased
under fructose feeding and nearly doubled upon FF treatment.
Absolute TAG-levels were determined in rat serum at the
beginning (day 0) and at the end of the study (day 16, Fig 1B).
A significant increase of TAGs under fructose-feeding, and a
significant decrease by ,25% under FF treatment was observed.
The absolute levels of TAGs and DAGs (nmol/mg cell protein;
Fig 1B) were analyzed in rat liver and jejunum at the end of the
study. Without fructose-feeding rat jejunum contained about 10-
fold higher TAG-levels than rat liver. Upon fructose-feeding
TAG-levels decreased in the jejunum and increased in the liver,
while FF slightly increased TAGs in the jejunum (,20%) and
decreased TAGs in the liver (,50%) back to control group levels.
DAG-levels in the liver increased upon fructose-feeding and more
than doubled upon FF treatment. In contrast, baseline DAG-levels
(Fig 1B) in the jejunum were 2-fold lower than in the liver, but did
not change significantly under FF treatment. Fig 1C shows the
sums of DAG- and TAG-species in the rat serum samples as an
indicator for the total amount of DAGs/TAGs in rat serum.
DAG-levels increased significantly by day 20 under fructose
feeding and were reduced to control levels by FF treatment. The
same was true for total TAGs, which increased upon fructose-
feeding and decreased back to control levels by FF treatment.
DAG-species analysis
As a next step, individual DAG-species were determined in rat
liver and rat serum at the three points of time. Fig 2A shows the
DAG-species in rat liver. Given are the mean values of the sums of
chain length of DAG-species (C32, C34, C36, C38) and the sums
of degree of desaturation (saturated to hexa-desaturated). The
complete data for the single DAG-species are shown in Fig. S1.
During fructose-feeding, DAG-species containing 3 or more
double bonds decreased, accompanied by an increase of species
containing 2 or less double bonds. This increase is only present in
the FA-species with 14, 16 or 18 carbons (C32, C34), while the
C38-containing DAG-species decreased. FF-treatment caused
variable changes of DAG-species. The short-chain DAG-species
(32:0, 32:1 and 32:2; Fig. S1) decreased, as did DAG-species 34:0,
34:2 and 34:3, while DAG 34:1 increased. The longer-chain
mono- and poly-unsaturated DAG-species 36:1, 36:2, 36:4, 38:3,
38:4 and 38:5 increased, while DAG 36:3, 38:2 and 38:6
decreased. The overall increase of DAG-levels was attributable
to two species, DAG 34:1 and DAG 36:2, both may possibly
contain FA 18:1.
It is interesting to note that only a few DAG-species (34:1, 34:2,
34:3, 36:2, 36:3, 36:4 and 38:4) were detectable in rat serum
Fenofibrate Treatment of Fructose-Fed Rats - Neutral Lipids
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(Fig 2B). There was no difference between the groups on day 0.
After 14 days of fructose feeding DAG 34:1 and 36:2 increased,
which may also contain FA 18:1, while DAG 36:4 decreased. FF
treatment decreased DAG-species 34:2, 34:3, 36:3 and 36:4 to
below control levels. It is also notable that DAG 36:2 (18:1/18:1 or
18:0/18:2) is not influenced by FF treatment in rat serum.
TAG-species analysis
TAG-species in the liver (Fig 3) are again displayed as means of
sums of TAG-chain lengths (C46, C48, C50, C52, C54, C56, C58)
and of sums of degree of desaturation (sat – deca). The levels of
individual TAG-species are shown in Fig S2 (liver) and S3 (serum).
Upon fructose-feeding TAG-species containing 4 or more double
bonds decreased, while the species containing 3 or less double
bonds increased. FF treatment decreased the concentration of
Table 1. Clinical chemistry data, organ weight, food and water consumption.
initial final
fructose-free fructose-fed FF fructose-free fructose-fed FF
Cholesterol [mmol/l] 2.1860.39 2.6360.40 2.4560.49 2.2560.50 2.4060.41 1.3860.32*
Triglycerides [mmol/l] 2.1760.53 2.7360.93 2.6660.40 1.9860.58 3.1160.95** 1.4160.36**
Phospholipids [mmol/l] 2.0960.23 2.6460.31 2.6260.27 2.1960.39 2.6860.30** 1.7160.18**
Body weight [g] 350624.41 360613.98 353615.82 370625.84 382619.75 376618.11
Liver weight [g liver/animal] - - - 14.9561.35 17.4961.41* 24.0362.88**
rel. water consumption/100 g BW [g/d/animal] 26.93 22.64 22.31 22.59 17.63 19.45
abs food consumption [g/d/animal] 37.82 61.39 77.35 36.03 69.80 46.88
ASAT [u/l] 145.17636.59 120.17626.88 115.17622.89 111.00632.60 78.5066.72* 81.50639.52
ALAT [u/l] 76.6767.84 71.83615.85 68.50610.63 70.3369.81 61.83610.38 54.50612.93
AP [u/l] 228.33631.43 225.67618.44 216.50638.21 207.17629.19 200.33621.82 248.33636.38*
Values determined in study 1. Values given are mean values of the 6 animals/group with standard deviation included. Significant changes are indicated using *: P,0.05;
**: P,0.01; ***: P,0,001. ASAT: aspartate aminotransferase, ALAT: alanine aminotransferase, AP: alkaline phosphatase (AP).
doi:10.1371/journal.pone.0106849.t001
Figure 1. Tissue weights and overall TAG- and DAG-levels. A Organ weight of the animals after the end of treatment; B TAG-levels in rat liver,
jejunum and serum and DAG-levels in rat liver and rat jejunum; C Sums of TAG- and DAG-species in rat serum. Tissue samples were taken during
study 1, serum samples were taken during study 2; the control group is shown as black bar, the fructose-fed group is shown as red bar and the FF
treated group is shown as a blue bar; values given are means6s.d.; significant changes are indicated using *: P,0.05; **: P,0.01; ***: P,0,001.
doi:10.1371/journal.pone.0106849.g001
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almost all TAG-species. However, it is interesting to note that the
absolute levels of TAGs in the FF-group were lower than at
baseline, except TAG 50:2, TAG 52:1, TAG 52:2, TAG 54:2 and
TAG 54:3.
In contrast to DAG-species, there were more TAG-species
detectable in rat serum than in the liver (Fig S3). The groups
showed only marginal differences in TAG-species levels before
treatment. After 14 days of fructose most of the TAG-species
increased in rat serum with the exception of the highly unsaturated
long-chain TAG-species (56 and more carbons combined with 6
or more double bonds, Fig S3). FF treatment completely reversed
this species shift. With the exception of TAG 52:2, all TAG-species
were reduced to levels well below the levels in the rats of the
untreated and unfed group. In total a clear trend is visible: The
abundance of TAG-species C50, C52 and C54 is highest upon
normal diet; fructose-feeding dramatically increased TAG-species
C46, C48, C50 and C52 containing short-chain FAs (C12, C14,
C16 and C18), while the TAG-species C56 and C58 containing
long-chain FAs (C20 and C22) decreased.
Total hydrolysate fatty acids species analysis
In the next set of experiments, total hydrolysate fatty acid
species levels (FA) in rat liver (Fig 4A) were determined.
Concentrations of liver total hydrolysate FAs during fructose-
feeding were lower for FAs 15:0, 17:0, 18:2 (n-6), 22:4 (n-6) and
22:5 (n-3). Interestingly, FA 14:0, which is generally not released
Figure 2. DAG-species in rat liver and serum. DAG-species in A rat liver and B rat serum. Values given are means6s.d. of the sums of the
different chain lengths (C32 – C38) on the left and degree of desaturation (sat – hexa) on the right. Serum data is shown for day 14 and day 20; the
control group is shown as black bar, the fructose-fed group is shown as red bar and the FF treated group is shown as a blue bar; significant changes
are indicated using *: P,0.05; **: P,0.01; ***: P,0,001.
doi:10.1371/journal.pone.0106849.g002
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by fatty acid synthase increased by about 30% during fructose-
feeding. Also increased were FAs 16:1 (n-7), 18:1 (n-9) and 20:3 (n-
6), with the other species displaying no change. During FF
treatment the FA-species 14:0, 15.0, 17:0, 16:1 (n-7), 18:1 (n-7),
22:4 (n-6) and 22:5 (n-3) decreased, while FAs 16:0, 18:0, 18:1 (n-
9), 20:3 (n-6), 20:4 (n-6) and 20:5 (n-3) increased.
In the jejunum, total hydrolysate FAs generally decreased under
fructose-feeding, FF treatment tended to increase FA 14:0, FA
18:0, FA 20:0, and FA 22:0, while the other total hydrolysate FA-
species remained unchanged. None of these changes reached
significance.
In addition, more NEFA-species were present in the jejunum,
but no significant changes were seen upon fructose-feeding or FF
treatment (data not shown).
The concentrations of total FAs in serum were determined in all
three groups at day 0, day 14 (before FF treatment), and at day 20
(Fig 4B). Total FA-levels at day 0 were higher in the fructose-
feeding group and the FF group. In the course of fructose-feeding,
there was an increase in the short-chain FAs 14:0, 16:0, 16:1 (n-7)
and 18:1 (n-7). In contrast, the abundance of long-chain FAs was
reduced under fructose feeding, indicative of an impairment of
elongase activity during metabolic (fructose) challenge. The
increase of FA 18:1 (n-7) may be due to increased amounts of
substrate FA 16:1 (n-7). Serum FA-levels of the fructose and the FF
group were almost identical after 14 days of fructose-feeding and
before FF treatment. The values at day 20 showed a further
increase of short-chain FAs and a decrease of long-chain FAs upon
fructose-feeding. FF treatment significantly reduced all FA levels,
short-chain and long-chain, to or below baseline levels.
Non-esterified fatty acid species analysis
The non-esterified fatty acid (NEFA)-species in the rat liver
that significantly changed upon treatment are shown in Fig 5A.
NEFAs increased during fructose-feeding, with significantly higher
Figure 3. TAG-species in rat liver. Values given are means6s.d. of the sums of the different chain lengths (C46–C60) on the left and degree of
desaturation (sat – deca) on the right. Serum data is shown for day 14 and day 20; the control group is shown as black bar, the fructose-fed group is
shown as red bar and the FF treated group is shown as a blue bar; significant changes are indicated using *: P,0.05; **: P,0.01; ***: P,0,001.
doi:10.1371/journal.pone.0106849.g003
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concentrations of FA 16:1 (n-7). Interestingly, during FF treatment
FA 16:1 (n-7) decreased in rat liver, while FA 16:0, FA 18:0 FA,
18:1 (n-9) and FA 20:4 (n-6) increased significantly.
NEFAs at day 0 again showed higher levels for the fructose and
the FF group (Fig 5B). During fructose feeding the NEFAs FA
14:0, FA 16:0, FA 16:1 (n-7), FA 18:0 and FA 18:1 (n-7) increased,
while FA 18:2 (n-6) and FA 18:3 (n-7) decreased. NEFA-levels in
the fructose-feeding and the FF group were identical before
treatment. At day 20 the fructose-feeding group showed the same
pattern compared to controls. Again, FF treatment reduced all
NEFA levels to or below control group levels.
Interrelation analysis of TAG-, DAG- and total FA-species
The TAG/DAG- and FA-species were all quantified and the
changes of species levels between the groups were plotted in an
alternate display format (Fig 6). This figure contains just the
section of TAGs with 54 C, DAGs with 36 C and FAs with 18 C to
exemplify the principle. The complete displays are in Fig S4 and
S5. With this information it is possible to determine graphically
which FA and DAG-combinations might actually part of the
corresponding TAG -species makeup. It is of course necessary to
restrict the interpretation of this analysis to FA-species changes
that reach significance.
We will give an example of this visualization. We have an
increase of TAG 54:2 in the fructose-fed group compared to
Figure 4. Total hydrolysate fatty acids in rat liver and serum. FA-species A total hydrolysate FA-species in rat liver B total hydrolysate FA-
species in rat serum. The control group is shown as black bar the fructose-fed group is shown as red bar and the FF treated group is shown as a blue
bar; values given are means6s.d.; significant changes are indicated using *: P,0.05; **: P,0.01; ***: P,0,001.
doi:10.1371/journal.pone.0106849.g004
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Figure 5. NEFA-species in rat liver and rat serum. A NEFA-species in rat liver homocysteine in rat serum; B NEFA-species in rat serum. The
control group is shown as black bar, the fructose-fed group is shown as red bar and the FF treated group is shown as a blue bar; values given are
means6s.d.; significant changes are indicated using *: P,0.05; **: P,0.01; ***: P,0,001.
doi:10.1371/journal.pone.0106849.g005
Figure 6. Alternate display format of TAG/DAG-species and FA-species. A fructose-feeding vs control in rat liver; B FF treatment vs
Fructose-feeding in rat liver; C fructose-feeding vs control in rat serum; D FF treatment vs Fructose-feeding in rat serum; An algorithm was developed
to generate the alternate display form of DAG/TAG-species. In the diagrams the species shown in red have increased levels between the two
respective groups, while a blue color indicates a decreased level of the respective species between the two groups. A black coloring indicates no
change of the species between the two groups. All species have been colored if the difference of levels between the two groups were .5% of the
total amount of the higher level, regardless of the significance of the change. For clarity, only the sections of the diagram containing the
combinations of DAG C36 With FA C18 to yield TAG C54 are shown. If there is a fatty acid-DAG combination present with the same direction of
change as the corresponding TAG-species, then this combination seems at least to contribute to the composition of the TAG-species. Significant
changes are indicated using *: P,0.05; **: P,0.01; ***: P,0,001.
doi:10.1371/journal.pone.0106849.g006
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the controls in rat liver (Fig 6A). Considering the data of the
DAG- and FA-species in this range (36 C for DAGs and 18 C for
Fas), it seems most likely that TAG 54:2 consists of a combination
of DAG 36:1 and FA 18:1 because both of those species are also
increased, while FA 18:0, part of the potential combination DAG
36:2 and FA 18:0, is decreased. With these measurements of
TAG/DAG-species it is possible to determine the most likely FA-
combinations of the TAG/DAG-species (Fig S4).
It is also possible to determine the FA-species that converts a
DAG-species into a corresponding TAG-species. For example, in
the TAG-cluster containing 58 carbons (Fig S4), the species can be
synthesized by esterification of DAG 38:5 with FA 20:0, 20:1,
20:2, 20:3, 20:4 or 20:5 respectively, to yield the resulting TAG-
species (TAG 58:5, 58:6, 58:7, 58:8, 58:9 or 58:10). Of these six
species TAG 58:9 and 58:10 decreased significantly under fructose
feeding. The possible FA-DAG-combinations in which both
components (FA and DAG) decreased are FA 20:4/DAG 38:5
for TAG 58:9; and FA 20:4/DAG 38:6 for TAG 58:10. These
combinations are therefore likely to contribute to the compostion
of those TAG-species. With this type of data analysis a relation of
the up- or down-regulation of desaturation and elongation can be
displayed graphically.
The same type of analysis has been performed for serum DAG/
TAG/FA-species on day 20 (Fig S5). It is interesting to note that
there were far less DAG-species present in rat serum but more
TAG-species. Fructose-feeding induces the same pattern of
increase/decrease of TAG-species in rat serum as in rat liver, as
does FF treatment. Interestingly, all FA-species, except 20:3
decrease upon FF treatment.
VLDL secretion was also monitored (Fig 7). VLDL secretion
after Triton treatment was doubled upon fructose feeding, while
FF treatment decreased VLDL-secretion back to control levels.
Discussion
In the rat study presented here, most significant changes of lipid
species occurred in rat liver, as a center of lipid synthesis and
remodeling. TAGs are synthesized by esterification of DAGs
through DGAT (consisting of two subtypes DGAT1 and DGAT2)
with CoA-activated FAs being the substrates. The activity of
DGAT is especially high in liver and intestine [42]. DGAT1 is
most active at high substrate levels, which occur during high levels
of lipolysis or during exposure to a high fat diet. DGAT2 on the
other hand is most active at low substrate levels, which are
connected to endogenous de novo FA-synthesis [43]. This
endogenous synthesis is performed by fatty acid synthase, a
multi-centered enzyme present in vivo as a dimer, which
synthesizes fatty acids by incorporating C2-units until a chain-
length of 16 carbons is reached and palmitate is released from the
FAS-complex [44]. Fructose feeding increased FA 12:0 and 14:0,
which are usually not liberated from FAS, in rat serum, while FF
treatment reduced both species below control levels. Thus,
fructose feeding seems to reduce the capacity of FAS for fatty
acid binding of intermediates #C16:0 palmitate. This may be due
to a metabolic overload of acetate caused by ingestion of fructose.
The synthesis of other FA-species is then essentially achieved
through elongation and desaturation of palmitate. Elongation
involves elongases (ELOVL1/3/5/6) while desaturation is
achieved by desaturases (SCD1-6, D5D, D6D) [45]. Under the
influence of a diet high in carbohydrates (fructose-feeding)
DGAT2 is the major enzyme active in the synthesis of TAGs as
the storage form of FAs. In this study, TAG-levels in rat liver
almost doubled upon fructose-feeding compared to standard diet
and were decreased by FF-treatment to control levels. This
indicates that DGAT2 inhibition is mediated by FF. It has been
shown that SCD1 and DGAT2 are localized close to each other
on the ER, indicating a participation of SCD1 in the synthesis of
TAGs and the incorporation of MUFAs into TAGs [46]. This is in
agreement with the presented data showing decreased FA16:1n7,
the product of desaturation of FA16:0 by SCD1, in both NEFAs
and total FAs. On the other hand, FA 18:1n9, which is also a
product of SCD1, was increased in NEFAs and total FAs upon FF-
treatment. This increase of FA 18:1n9 could be traced through
most lipid species in liver and serum (e.g. CE 18:1) under FF-
treatment. This might indicate that there is also SOAT1 activation
by channeling oleate towards cholesteryl ester synthesis. Arachi-
donic acid (FA 20:4n6) is derived from linoleate through
desaturation (D6D and D5D) and elongation (ELOVL5). In rat
liver, FF-treatment significantly increased the level of the pro-
inflammatory FA 20:4 (n-6) in total FAs and NEFAs, accompanied
by a significant increase of the precursor FA20:3 (n-6) and a
significant decrease of the corresponding precursor FA18:2 (n-6) in
total FAs. In the NEFA-fraction, the FA18:2 (n-6) concentration
remained unchanged compared to fructose-feeding, indicative of
elongase (ELOVL5) and desaturase (D5D) activation towards the
n-6-series induced by FF-treatment in rat liver. Most FA-species of
the anti-inflammatory n-3-series decreased or remained below
detection levels.
It is interesting to note that the weight of the liver increases
significantly under FF treatment. The underlying mechanism is
unclear. It might be due to the increased metabolic action induced
by PPARa-activation resulting in an increased hepatic activity.
In order to verify the hypothesis described above, the linkage of
transcriptional data to the lipid metabolite profiles is attempted as
an extension of the present study.
Summary
The present study presents a detailed investigation of lipid
species during fructose challenge and fenofibrate treatment in rats.
To our knowledge, it is the most complete lipidomic analysis on FF
effects conducted to date. In the first part, we determined the levels
of TAG- and DAG-species as well as the amounts of total
hydrolysis FA- and NEFA-species in rat liver and rat serum. Short-
chain TAGs increased in serum and liver upon fructose-feeding
and almost all TAG-species decreased under FF treatment, while
longer-chain, more unsaturated DAG-levels (36:1, 36:2, 36:4,
Figure 7. VLDL-secretion after FF treatment. The control group is
shown in black, the fructose-fed group is shown in red and the FF
treated group is shown in blue; values given are means6s.d.; significant
changes are indicated using *: P,0.05; **: P,0.01; ***: P,0,001.
doi:10.1371/journal.pone.0106849.g007
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38:3, 38:4, 38:5) increased upon FF treatment in rat liver and
decreased in rat serum. FAs, especially short-chain FAs (12:0, 14:0,
16:0) and VLDL secretion increased during fructose-challenge and
decreased to control levels during FF treatment. Fructose
challenge of de novo fatty acid synthesis through fatty acid
synthase (FAS) may enhance the release of #16:0 chain length
fatty acids, a process that is reversed by FF-mediated PPARa-
activation.
In addition, we present a correlation diagram of the data that
combines theoretical compositions of TAG and DAG with relative
abundances of TAG, DAG and FA species, thereby providing a
qualitative view on probable TAG and DAG compositions.
Supporting Information
Figure S1 DAG-species in rat liver and rat serum. The
control group is shown as black bar, the fructose-fed group is
shown as red bar and the FF treated group is shown as a blue bar;
values given are means6s.d.; significant changes are indicated
using *: P,0.05; **: P,0.01; ***: P,0,001.
(TIF)
Figure S2 TAG-species in rat liver. The control group is
shown as black bar, the fructose-fed group is shown as red bar and
the FF treated group is shown as a blue bar; values given are
means6s.d.; significant changes are indicated using *: P,0.05; **:
P,0.01; ***: P,0,001.
(TIF)
Figure S3 TAG-species in rat serum. The control group is
shown as black bar, the fructose-fed group is shown as red bar and
the FF treated group is shown as a blue bar; values given are
means6s.d.; significant changes are indicated using *: P,0.05; **:
P,0.01; ***: P,0,001.
(TIF)
Figure S4 Alternate display format of TAG/DAG-spe-
cies and FA-species. A fructose-feeding vs control in rat liver; B
FF treatment vs Fructose-feeding in rat liver; An algorithm was
developed to generate the alternate display form of DAG/TAG-
species. In the diagrams the species shown in red were increased
upon fructose-feeding compared to baseline, while a blue color
indicates a decreased level of the respective species. For clarity,
only the sections of the diagram containing the combinations of
DAG C36 With FA C18 to yield TAG C54 are shown. If there is a
fatty acid combination present with the same direction of change
as the corresponding TAG-species, then this combination should
be at least the biggest contributor to the TAG-species. Significant
changes are indicated using *: P,0.05; **: P,0.01; ***: P,0,001.
(TIF)
Figure S5 Alternate display format of TAG/DAG-spe-
cies and FA-species. A fructose-feeding vs control in rat serum;
B FF treatment vs Fructose-feeding in rat serum; An algorithm
was developed to generate the alternate display form of DAG/
TAG-species. In the diagrams the species shown in red were
increased upon fructose-feeding compared to baseline, while a
blue color indicates a decreased level of the respective species. For
clarity, only the sections of the diagram containing the
combinations of DAG C36 With FA C18 to yield TAG C54 are
shown. If there is a fatty acid combination present with the same
direction of change as the corresponding TAG-species, then this
combination should be at least the biggest contributor to the TAG-
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